Roche instigates new cobas m 511 analyzer in hematology testing

Roche declared that its new hematology testing solution, the cobas m 511 integrated hematology analyzer has received 510(k) clearance from the U.S Food and Drug Administration.

The cobas m 511 analyzer features patented Bloodhound technology which is designed to meet the challenges of hematology testing by combining a cell counter, slide maker and stainer and a digital morphology analyzer into one integrated solution. Now, Laboratories can signal the Complete blood count or CBC, white blood cell differential and reticulocyte results, and prepare, stain and analyze blood smears for abnormal results through a single, integrated process.

Traditional hematology testing which is labor and time intensive entails a larger blood sample that often needs to be processed using innumerable methods to obtain results.

Manual Morphology may be difficult for laboratorians to interpret consistently, due to the varying qualities of stain and blood smears.

Chief Medical Officer Dr. Alan Wright, Roche Diagnostics Corporation said “This integrated laboratory solution is a game-changer for patients and clinicians by offering faster access to abnormal results and potential accuracy gains through digitalization. One in 76 people in the U.S. are born with a blood disorder, making this aid in the diagnosis of blood diseases like anemia and leukemia a significant advancement.”

The cobas m 511 analyzer uses a unique approach to enter the new field of digital hematology through patented Bloodhound technology for printing, staining and imaging. This technology uses only 30μL of blood to print a monolayer onto the slide, stains with an improved method for further analysis of the morphology and enables classification of cells displayed on a viewing station.